# Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer

> **NCT01491204** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 25 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Paclitaxel+HM30181

## Key facts

- **NCT ID:** NCT01491204
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491204, "Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01491204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*